Ingenhoven, T, Lafay, P, Rinne, T, etal. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010; 71(1): 14–25.
Lieb, K, Völlm, B, Rücker, G, etal. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010; 196(1): 4–12.
Stoffers, JBA, Völlm, G, Rücker, A, etal. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010; (6): CD005653.
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006; 67(7): 1042–1046.
Hilger, E, Barnas, C, Kasper, S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003; 4(1): 42–44.
Villeneuve, E, Lemelin, S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005; 66(10): 1298–1303.
Nickel, M, Muehlbacher, M, Nickel, C, etal. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006; 163(5): 833–838.
Bellino, S, Bozzatello, P, Rinaldi, C, Bogetto, F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat. 2011; 2011: 680194.
Grootens, KP, Verkes, RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry. 2005; 38(01): 20–23.
Bogenschutz, MP, Nurnberg, G. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004; 65(1): 104–109.
Linehan, MM, McDavid, JD, Brown, MZ, Sayrs, JH, Gallop, RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008; 69(6): 999–1005.
Schulz, CS, Camlin, KL, Berry, SA, Jesberger, JA. Olanzapine safety and efficacy in patients with borderline personality disorder and co-morbid dysthymia. Biol Psychiatry. 1999; 46(10): 1429–1435.
Zanarini, MC, Frankenburg, FR, Parachini, EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65(7): 903–907.
Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001; 62(11): 849–854.
Keshavan, M, Shad, M, Soloff, P, Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res. 2004; 71(1): 97–101.
Koenigsberg, HW, Reynolds, D, Goodman, M, etal. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003; 64(6): 628–634.
Rocca, P, Marchiaro, L, Cocuzza, E, Bogetto, F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002; 63(3): 241–244.
Vauquelin, G, Bostoen, S, Vanderheyden, P, Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol. 2012; 385(4): 337–372.
Fakra, E, Azorin, J. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012; 13(3): 1923–1935.
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158(4): 518–526.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9): 789–796.
Meltzer, , Herbert, Y. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997; 14(1): 1–20.
Chengappa, KN, Ebeling, T, Kang, JS, Levine, J, Parepally, H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999; 60(7): 477–484.
Vohra, AK. Treatment of severe borderline personality disorder with clozapine. Indian J Psychiatry. 2010; 52(3): 267–269.
Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998; 59(3): 103–107.
Swinton, M. Clozapine in severe borderline personality disorder. The Journal of Forensic Psychiatry. 2001; 12(3): 580–591.
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993; 34(6): 402–405.
Buckley, P, Bartell, J, Donenwirth, K, etal. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995; 23(4): 607–611.
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351–1371.
Chengappa, KNR, Vasile, J, Levine, J, etal. Clozapine: its impact on aggressive behaviour among patients in a state psychiatric hospital. Schizophr Res. 2002; 53(1–2): 1–6.
Citrome, L, Volavka, J, Czobor, P, etal. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001; 52(11): 1510–1514.
Dalal, B, Larkin, E, Leese, M, Taylor, PJ. Clozapine treatment of long-standing schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Crim Behav Ment Health. 1999; 9(2): 168–178.
Rabinowitz, J, Avnon, M, Rosenberg, V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996; 22(3): 249–255.
Ratey, JJ, Leveroni, C, Kilmer, D, Gutheil, C. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry. 1993; 54(6): 219–223.
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry. 1999; 60(Suppl 12): 43–46.
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006; 63(6): 622–629.
Hart, SD, Cox, DN, Hare, RD. The Hare Psychopathy Checklist: Screening Version (PCL: SV). Multi-Health Systems, Inc.; 1995. Again book (1st ed). Toronto, ON, Canada.
Guy, W. The Clinical Global Impression Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, MD: U.S. Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976:218–222.
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993; 34(6): 402–405.
Binks, CA, Fenton, M, McCarthy, L, etal. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2006; (1): CD005652.
Soloff, PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioural dysregulation. Bull Menninger Clin. 1997; 62(2): 195–214.
Webster, C, Douglas, K, Eaves, D, Hart, S. HCR-20: Assessing Risk for Violence. Version 2; 1992. Burnaby, BC, Canada: Mental Health, Law and Policy Institute, Simon Fraser University.
World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992; 50.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
Glazer, GM, Dickson, RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry. 1998; 59(Suppl 3): 8–14.
Spina, E, Avenoso, A, Facciolà, G, etal. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000; 148(1): 83–89.
Humbert-Claude, M, Davenas, E, Gbahou, F, Vincent, L, Arrang, JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl). 2012; 220(1): 225–241.
Stahl, SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz; 1999.
Harrison, AA, Everitt, BJ, Robbins, TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl). 1997; 133(4): 329–342.
Vukhac, K, Sankoorika, EL, Yanyan, Wang. Dopamine D2L receptor-and age-related reduction in offensive aggression. Neuroreport. 2001; 12(5): 1035–1038.
Wade, TR, Wit, HD, Richards, JB. Effects of dopaminergic drugs on delayed reward as a measure of impulsive behaviour in rats. Psychopharmacology (Berl). 2000; 150(1): 90–101.
Chotai, J, Kullgren, J, Åsberg, M. CSF monoamine metabolites in relation to the diagnostic interview for borderline patients (DIB). Neuropsychobiology. 1998; 38(4): 207–212.
Coccaro, EF, Silk, KR, ed. Neurotransmitter function in personality disorders. In: Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998: 1–25.
Friedel, RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004; 29(6): 1029–1039.
Adams, DB. Brain mechanisms for offence, defence, and submission. Behav Brain Sci. 1979; 2(2): 201–213.
Berman, ME, Tracy, JI, Coccaro, EF. The serotonin hypothesis of aggression revisited. Clin Psychol Rev. 1997; 17(6): 651–665.
Brown, GL. Aggression, suicide, and serotonin: relationships of CSF amine metabolites. Am J Psychiatry. 1982; 139(6): 741–746.
de Boer, FS, Koolhaas, JM. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005; 526(1–3): 125–139.
Gowin, JL, Swann, AC, Moeller, FG, Lane, SD. Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl). 2010; 210(4): 521–531.
Miczek, KA, Fish, EW, Joseph, F, De Almeida, RM. Social and neural determinants of aggressive behaviour: pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology (Berl). 2002; 163(3): 434–458.
Moss, HB, Yao, JK, Panzak, GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry. 1990; 28(4): 325–338.
Constantino, JN, Morris, JA, Murphy, DL. CSF 5-HIAA and family history of antisocial personality disorder in newborns. Am J Psychiatry. 1997; 154(2): 1771–1773.
Krakowski, M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003; 15(3): 294–305.
Umukoro, S, Aladeokin, AC, Eduviere, AT. Aggressive behavior: a comprehensive review of its neurochemical mechanisms and management. Aggression and Violent Behavior. 2012; 18(2): 195–203.
Paris, P. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology?
Compr Psychiatry. 1997; 38(4): 237–242.
Bateman, AW, Tyrer, P. Psychological treatment for personality disorders. Advances in Psychiatric Treatment. 2004; 10(5): 378–388.
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008; 22(8): 671–692.
Nelson, KJ, Schulz, CS. Treatment advances in borderline personality disorder. Psychiatric Annals. 2012; 42(2): 59–64.
Dolan, M. Psychopathic personality in young people. Advances in Psychiatric Treatment. 2004; 10(6): 466–473.
Hare, RD. Psychopathy, affect and behaviour. In: Cooke DJ, Forth AE, Hare RD, eds. Psychopathy: Theory, Research and Implications for Society. Dordrecht, the Netherlands: Springer; 1998: 105–137.
Salekin, RT, Rogers, R, Sewell, KW. A review and meta-analysis of the Psychopathy Checklist and Psychopathy Checklist-Revised: predictive validity of dangerousness. Clinical Psychology: Science and Practice. 1996; 3(3): 203–215.
Buckholtz, JW, Treadway, MT, Cowan, RL, etal. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci. 2010; 13(4): 419–421.
Dolan, MC, Anderson, IM. The relationship between serotonergic function and the Psychopathy Checklist: Screening Version. J Psychopharmacol. 2003; 17(2): 216–222.
Soderstrom, H, Blennow, K, Sjodin, AK, Forsman, A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry. 2003; 74(7): 918–921.
Barkataki, I, Kumar, V, Das, M, Taylor, P, Sharma, T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav Brain Res. 2006; 169(2): 239–247.
Kumari, V, Das, M, Taylor, PJ, etal. Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder. Schizoph Res. 2009; 110(1–3): 47–58.
Yang, Y, Raine, R. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: a meta-analysis. Psychiatry Res. 2009; 174(2): 81–88.
Chopra, HD, Beatson, JA. Psychotic symptoms in borderline personality disorder. Am J Psychiatry. 1986; 143(12): 1605–1607.
Kendal, T, Pilling, S, Tyrer, P, etal. Guidelines: Borderline and Antisocial Personality Disorders: Summary of NICE Guidance. BMJ. 2009; 338(7689): 293–295.
Volavka, J, Citrome, L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res. 1999; 35(Suppl): S23–S33.